Chart Industries GTLS Biomedical — Severance Costs1
Discontinued — last reported Q4 '15
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Chart Industries in its filing.
Tagged under the XBRL concept us-gaap:SeveranceCosts1.
The official record: Chart Industries’s 10-K, filed February 26, 2016, on SEC EDGAR. View the filing →
Questions, answered.
- What does biomedical — severance costs1 mean?
- The total costs incurred from laying off or restructuring staff within the Biomedical business unit.
- How do you interpret biomedical — severance costs1?
- An increase suggests active restructuring or downsizing within the segment, which may signal short-term margin pressure but potential long-term efficiency gains. A decrease indicates a more stable workforce environment or the conclusion of a specific restructuring program.
- How does biomedical — severance costs1 compare across companies?
- Comparable to restructuring charges or severance-related operating expenses reported by peers in the life sciences or specialized industrial equipment sectors.